BEHAVIORAL FAMILY COUNSELING AND NALTREXONE FOR MALE OPIOID-DEPENDENT PATIENTS William Fals-Stewart, Ph.D. Research Institute on Addictions.

Slides:



Advertisements
Similar presentations
13 Principles of Effective Addictions Treatment
Advertisements

Predictors of Change in HIV Risk Factors for Adolescents Admitted to Substance Abuse Treatment Passetti, L. L., Garner, B. R., Funk, R., Godley, S. H.,
Background: The low retention rates among African Americans in substance abuse treatment (Milligan et al., 2004) combined with the limited number of treatments.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence July–August 2013.
HIV Risk Behaviors and Alcohol Intoxication among Injection Drug Users in Puerto Rico Tomás D. Matos, MS Center for Addiction Studies Universidad Central.
Killing the Pain: Prescription Drug Abuse and Other Risky Behaviors in Rural Appalachia Jennifer R. Havens, PhD, MPH Department of Behavioral Science Center.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence September–October 2008.
Evidence-Based Treatment Community Reinforcement Approach (CRA) Robert J. Meyers, Ph.D. Jane Ellen Smith, Ph.D. University of New Mexico.
Journal Club Alcohol and Health: Current Evidence May–June 2005.
Motivational Interviewing to Improve Treatment Engagement and Outcome* The effect of one session on retention Research findings from the NIDA Clinical.
Journal Club Alcohol, Other Drugs, and Health: Current Evidence November–December 2008.
Evaluating Cocaine Use Outcome Measures: Relationships with Long Term Cocaine Use and Functioning Brian D. Kiluk, Ph.D. Kathleen M. Carroll, Ph.D. Yale.
A Health Based Approach Within The UN Conventions: Examples Of Practice Fay Watson, Vice Chair: EU Civil Society Forum on Drugs.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
CYT Family Sessions Impact on CYT Process and Outcome Susan H. Godley, Rodney Funk, Michael L. Dennis, & Mark D. Godley, Chestnut Health Systems.
Evidence for twelve step facilitation in the medical literature Jonathan Chick HLO’s meeting, York, March 2014.
® Introduction Low Back Pain Remedies and Procedures: Helpful or Harmful? Lauren Lyons, Terrell Benold, MD, Sandra Burge, PhD The University of Texas Health.
Continuing Care for Adolescents with Substance Use Disorders: Opportunities for Health Services Research Thomas M. Brady, Ph.D. Division of Epidemiology,
Low-Cost Contingency Management in Community Settings
Addiction Treatment Works! Through Collaboration and Problem Solving amongst all disciplines.
Practical Application of Contingency Management Michael J. McCann, MA Matrix Institute on Addictions.
SUBSTANCE USE DISORDERS GENERAL METHODS OF TREATMENT Inpatient Detoxification and Rehabilitation Outpatient Individual, Couple, or Family Counseling Self-help.
Factors that Influence Retention in Greek Therapeutic Communities Erianna Daliani MSc (Gerasimos Papanastasatos) KETHEA Research Dept. 11th European Conference.
Attractive Addiction Treatment...? Can we make addiction treatment engaging?
Audrey J. Brooks, PhD University of Arizona CA-AZ node.
For more information contact Alemi at
Evidence-Based Practice: Psychosocial Interventions Maxine Stitzer, Ph.D. Johns Hopkins Univ SOM NIDA Blending Conference June 3, 2008 Cincinnati, Ohio.
Principles of Drug Addiction Treatment (Section 5 continued…) UCLA Integrated Substance Abuse Programs Continuum of Care 1.
METHODS Sample n=245 Women, 24% White, 72% Average age, 36.5 Never married, 51% Referral Sources (%) 12-Month DSM-IV Substance Dependence Prior to Entering.
Chapter 11 Subset of Overview by Mental Health Disorders GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available.
Addiction Treatment as HIV Prevention Charles P. O’Brien, MD, PhD David Metzger, PhD George E. Woody, MD University of Pennsylvania Treatment Research.
Recovery Support Services and Client Outcomes: What do the Data Tell Us? Recovery Community Services Program Grantee Meeting December 14, 2007.
CARIBBEAN BASIN AND HISPANIC ADDICTION TECHNOLOGY TRANSFER CENTER Effects of a Two-facet Intervention to Reduce HIV Risk Behaviors Among Hispanic Drug.
Contingency Management Contingency management (CM) refers to the systematic application of basic principles delineated by workers in the field of the Experimental.
Are Incentives Effective in Improving Participation and Outcomes in Treatment for Substance-Abusing Offenders? Michael L. Prendergast, Ph.D. Elizabeth.
Increased exposure to an HIV risk reduction protocol associated with a reduction in drug abuse severity Louise F. Haynes 1 ; Rickey E. Carter 1 ; Amy E.
Elizabeth WellsDennis Daley School of Social WorkWestern Psychiatric Institute University of WashingtonUniversity of Pittsbu rgh Supported by Grants #
Farrokh Alemi, Ph.D., Mary Haack, Ph.D., Susie Nemes, Ph.D., Angela Harge, M.Ed., Heibatollah Baghi, Ph.D. This research was supported by a grant from.
Raymond F. Anton, MD for The COMBINE Study Research Group
What Makes Drug Courts Effective? Douglas B. Marlowe, J.D., Ph.D. Treatment Research Institute at the University of Pennsylvania TRI science addiction.
Abstinence Incentives for Methadone Maintained Stimulant Users: Outcomes for Those Testing Stimulant Positive vs Negative at Study Intake Maxine L. Stitzer.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Introduction Results and Conclusions On demographic variables, analyses revealed that ATR clients were more likely to be Hispanic and employed, whereas.
Methamphetamine: User Characteristics and Treatment Response Alice Huber, Ph.D. Steven Shoptaw, Ph.D. Richard A. Rawson, Ph.D. Paul Brethen, M.A. Walter.
Chapter 6 Subset of Overview by Gender GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available from
Abstinence Incentive Effects in Psychosocial Counseling Patients Testing Stimulant Positive vs Negative at Treatment Entry Maxine L. Stitzer Johns Hopkins.
Chapter 13 Subset of Overview by Crime and Violence GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available.
Table 1. Prediction model for maximum daily dose of buprenorphine-naloxone in a 12-week treatment condition Baseline Predictors Maximum Daily Dose Standardized.
California Addiction Training and Education Series Jeanne L. Obert, MFT, MSM Executive Director, Matrix Institute on Addictions Methamphetamine Behavioral.
Introduction Results and Conclusions Analyses of demographic and social variables revealed that women were more likely to have children, be living in a.
SMOKING in ADOLESCENTS with PSYCHIATRIC or ADDICTIVE DISORDERS.
CEACEA CENTROCENTRO DE ESTUDIOS EN ADICCION Testing an Intervention Model to Reduce HIV/AIDS Among Hispanic Drug Users Residing in Puerto Rico Robles RR,
Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.
Texas COSIG Project Gender Differences in Substance Use Severity and Psychopathology in Clients with Co-Occurring Disorders 5 th Annual COSIG Grantee Meeting.
Ready (or not) to graduate: Mental and physical health characteristics associated with completing public housing-based, substance abuse treatment in Key.
Combined Pharmacological and Behavioral Therapy and HIV Risk Reduction Jennifer Schroeder, David Epstein, Katherine Belendiuk, Jessica Willner-Reid, John.
Ten Years of Pharmacotherapy Trials in the CTN: An Overview.
Clinical Trial Finds That While Buprenorphine-Naloxone Maintenance Reduced Other Opioid Use Among Those Dependent on Prescription Opioids, 91% Were Not.
Chapter 9 Subset of Overview by Risk of Homelessness GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available.
Chapter 17 Subset of Overview by Type of Treatment GAIN Coordinating Center (11/21/2012). Normal, IL: Chestnut Health Systems. November Available.
Background and Rationale for COMBINE A Multisite Clinical Trial Sponsored by National Institute on Alcohol Abuse and Alcoholism NIH, DHHS Margaret E. Mattson,
Management of Substance Use Disorder Module P: Addiction-Focused Pharmacotherapy.
The DOT-Qualified Substance Abuse Professional (SAP) William “Reggie” Smith, MPA, CEAP, SAP.
Parental substance use, child protection and drug treatment services Dr Stephanie Taplin Professor Richard Mattick National Drug & Alcohol Research Centre,
PURPOSE BACKGROUND RESULTS STUDY DESIGN & METHODS HIV Risk Behaviors Among Male Prisoners Participating in a Randomized Clinical Trial of Methadone Maintenance.
Suboxone and Opioid Trends Joseph Merrill M.D., M.P.H. University of Washington June 16, 2009.
One-Year Post-Treatment COMBINE Study Drinking Outcomes Dennis M. Donovan, Ph.D. for the COMBINE Study Research Group Research Society on Alcoholism Baltimore,
Medication-Assisted Therapy at Coleman Profession Services
Do Alcoholics Respond to Placebo? Results from COMBINE
Pharmacologic Interventions for Unhealthy Drinking
Presentation transcript:

BEHAVIORAL FAMILY COUNSELING AND NALTREXONE FOR MALE OPIOID-DEPENDENT PATIENTS William Fals-Stewart, Ph.D. Research Institute on Addictions

Heroin Use: Scope of the Problem In U.S., Growing Problem –Most Common Primary Illicit Substance of Those Entering Treatment in U.S. –Cost Estimated to Be $30 Billion Annually –Only 20% of Those in Need of Treatment Actually Receive It Significant Problem Internationally

Pharmacological Treatment: NALTREXONE Opioid Antagonist – Blocks Subjective Reinforcing Effects of Opioid-Based Drugs Positive Outcomes for Motivated Patients –Physicians and Other Health Care Providers –Those Facing Employment Termination –Probationers and Others Facing Legal Sanctions

Use of Naltrexone in Community-Based Practice Despite Early Promise of Naltrexone, Not Widely Used in Community Practice Engagement and Compliance Problems –Common Delivery Approaches are Unwieldy –Standard Medication Delivery Methods Lead to Rampant Noncompliance

Enhancing Naltrexone Compliance: Two Methods Voucher-Based Reinforcement Methods Family/Significant Other (SO) Approaches

Voucher-Based Methods Recent Studies –Preston et al., 1999 –Carroll et al., 2001 Increase Compliance, Treatment Retention, and Opioid Abstinence During Period When Contingencies Were in Effect No Long-Term Follow-Up After Removal of Contingencies

Family-Based Approach: Behavioral Family Counseling (BFC) Spouse or Significant Other (SO) Observe Medication Taking “Medication Contract” is Established Between Patient and SO, Which is Monitored in Counseling SO Verbally (and Positively) Reinforces Patient’s Compliance

Behavioral Family Counseling & Medication Compliance: Previous Studies Disulfiram with Alcoholic Patients Naltrexone with Alcoholic Patients HIV Medication with Drug-Abusing Patients Lithium with Bipolar Patient

Aims of Present Study Would the Use of Medication Contracts Between Opioid Dependent Patients and SOs Enhance Naltrexone Compliance During Primary Treatment? What Are the Durability of Observed Effects After Primary Treatment is Completed?

Participants 124 Detoxified Opioid-Dependent Men Entering Outpatient Treatment Nonsubstance-Abusing SO (Intimate Partner, Parent, or Other Family Member) Willing to Participate in Treatment

Sociodemographics/Background Age32.4 (6.2) Years Education13.2 (2.1) Years Race/Ethnicity61% Minority Opioid Use6.6 (4.4) Years Family Member Spouses 35% Partner 13% Parent 36% Sibling 16%

Procedures Naltrexone Prescription to All Patients –50 mg/day Random Assignment: –Behavioral Family Counseling (BFC) –Individual-Based Treatment (IBT) Monitoring Naltrexone Compliance Within-Treatment and 12-Month Follow-Up Outcomes (Substance Use, Psychosocial)

Description of Treatments Behavioral Family Counseling (BFC) –Included Individual, Group, and Family Counseling during 24 weeks –“Recovery Contract” with Family Member; Included Daily Monitoring of Naltrexone Individual-Based Treatment –Included Individual and Group Counseling Only during 24 weeks –No Recovery Contract

Primary Measures Timeline Followback Interview –Calendar Assessment of Substance Use Frequency –Index: Percent Days Abstinent (PDA) Addiction Severity Index (ASI) –Composite Scores Urine Assay Results Pill Counts, Blister Packs

Results: Primary Outcomes Treatment Response Indicators –Naltrexone Compliance –Substance Use Posttreatment Outcomes –Substance Use –Psychosocial Functioning

Treatment Response Indicators Effects During Primary Treatment

Days of Naltrexone Ingestion

Percentage of Opioid-Free Urines During Treatment

Opioid Survival: During Treatment BFC IBT

Posttreatment Outcomes 12-Month Follow-Up

Percent Days Abstinent (PDA) Opioids: 12-Month Follow-Up

Percent Days Abstinent (PDA) All Drugs: 12-Month Follow-Up

BFC IBT

12-Month Follow-Up ASI Composite Scores

Mechanisms of Action: Mediational Analyses Examined Mediational Effect of Naltrexone Compliance on Treatment Response and Outcomes #Days of Naltrexone Use Was a Significant Partial Mediator of: –Substance Use During Treatment –Substance Use After Treatment –ASI Composite Score Differences

Summary Participants in BFC Had Significantly Better Treatment Response and Outcome Compared to IBT Treatment Effects Were Partially Mediated by Naltrexone Compliance

Limitations Engagement of Participants –Participant Recruitment Difficult –Reluctance to Take Naltrexone Requires Positive Family Participation –Often Difficult

Ongoing Research Combination of Voucher Reinforcement and BFC BFC + Naltrexone versus BFC w/o Naltrexone Cost-Benefit and Cost-Effectiveness Studies

Support National Institute on Drug Abuse –R01DA –R01DA –R01DA Supplement –R01DA –R01DA National Institute on Alcohol Abuse and Alcoholism –R21AA Alpha Foundation

Contact William Fals-Stewart, Ph.D. Research Institute on Addictions 1021 Main Street Buffalo, NY Slides available at: